Skip to content
Clinical Trials – home
The NetherlandsBack to the Netherlands

Clinical trials in Nieuwegein – page 7

161 clinical trials in Nieuwegein, The Netherlands across 2 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

The NetherlandsOur site in the NetherlandsKlinischOnderzoek.nl(opens in a new tab)
Nieuwegein at a glance
161
clinical trials
  • Research sites2
Type of trial
Recruitment status
Quick filters

161 trials in Nieuwegein

Open in trial search

Study on Apixaban for Preventing Stroke in Patients with Atrial Fibrillation and Stage 5 Chronic Kidney Disease

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Apixaban
  • Sponsor:Karolinska University Hospital

Study on Treatment Options for Patients with Oligometastatic Pancreatic Cancer: Comparing Oxaliplatin, Fluorouracil, Folinic Acid, and Drug Combination

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Fluorouracil
  • Sponsor:Universitaetsmedizin Goettingen

Study on Clopidogrel and Acetylsalicylic Acid for Patients with Coronary Artery Disease and Non-ST-segment Elevation Acute Coronary Syndrome

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Acetylsalicylic Acid
  • Sponsor:Sint Antonius Ziekenhuis Stichting

Randomized Phase 3 Study of Deupirfenidone (LYT‑100) versus Pirfenidone in Adults with Idiopathic Pulmonary Fibrosis

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Deupirfenidone
  • Sponsor:Puretech Lyt 100 Inc.

Plasma cell myeloma

Not yet recruiting

Ramantamig (JNJ-79635322) with drug combination versus standard therapy in newly diagnosed multiple myeloma patients not eligible for stem cell transplant

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Janssen Cilag International

Epcoritamab plus rituximab versus rituximab alone in elderly, frail or unfit patients with newly diagnosed diffuse large B‑cell lymphoma

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:65+ years
  • Substances:Epcoritamab
  • Sponsor:Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting

Chronic lymphocytic leukaemia+1

Not yet recruiting

Study of pirtobrutinib plus epcoritamab in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Epcoritamab
  • Sponsor:Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting

Infertility+2

Not yet recruiting

Micronised progesterone luteal-phase support improves live birth rates in women with unexplained infertility

Registered drug
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years
  • Substances:Progesterone, Micronised
  • Sponsor:Universitair Medisch Centrum Utrecht

Interstitial lung disease+2

Not yet recruiting

Long‑term Safety and Tolerability of Admilparant in Adults with Idiopathic or Progressive Pulmonary Fibrosis

InvestigationalNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:ADMILPARANT
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Pulmonary fibrosis

Not yet recruiting

A study to evaluate the effectiveness and safety of admilparant in patients with progressive pulmonary fibrosis

Investigational
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:ADMILPARANT
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

A study to evaluate the effectiveness and safety of admilparant in patients with idiopathic pulmonary fibrosis

Investigational
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:ADMILPARANT
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Study on Avelumab for Patients with Advanced Urothelial Cancer After Initial Chemotherapy

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Avelumab
  • Sponsor:Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)

Other cities in the Netherlands

The busiest research cities in the country

All 103 cities in the Netherlands

Clinical research in Nieuwegein

What the registry says about research in the country

01 Respiratory Medicine

Innovative research focusing on idiopathic pulmonary fibrosis and related conditions, evaluating new therapeutic approaches for lung diseases. Studies include assessment of novel treatments for systemic autoimmune rheumatic diseases with lung involvement.

  • Pulmonary Fibrosis Treatment
  • Interstitial Lung Disease
  • Rheumatic Disease-Related Lung Conditions

Multiple trials are investigating both targeted therapies and comprehensive treatment approaches.

02 Oncology Research

Comprehensive studies in cancer treatment, particularly focusing on prostate cancer and urothelial cancer. Advanced imaging techniques and novel therapeutic combinations are being evaluated for improved patient outcomes.

  • Advanced Colorectal Cancer
  • Acute Myeloid Leukemia
  • Bladder Cancer Therapeutics

Trials are exploring personalized treatment approaches and innovative drug combinations.

03 Neurological Disorders

Research initiatives addressing status epilepticus and post-cardiac arrest care. Studies include innovative approaches for treating dementia and related behavioral issues.

  • Post-Cardiac Arrest Care
  • Dementia Management
  • Stroke Prevention

Investigations focus on both acute neurological conditions and long-term management strategies.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.